Singapore markets closed
  • Straits Times Index

    2,973.87
    +0.87 (+0.03%)
     
  • S&P 500

    3,899.62
    -2.20 (-0.06%)
     
  • Dow

    31,561.82
    +26.31 (+0.08%)
     
  • Nasdaq

    13,565.15
    -23.68 (-0.17%)
     
  • BTC-USD

    49,605.11
    +1,521.09 (+3.16%)
     
  • CMC Crypto 200

    998.92
    +12.27 (+1.24%)
     
  • FTSE 100

    6,630.63
    +42.10 (+0.64%)
     
  • Gold

    1,724.70
    +1.70 (+0.10%)
     
  • Crude Oil

    61.03
    +0.39 (+0.64%)
     
  • 10-Yr Bond

    1.4330
    -0.0130 (-0.90%)
     
  • Nikkei

    29,408.17
    -255.33 (-0.86%)
     
  • Hang Seng

    29,095.86
    -356.71 (-1.21%)
     
  • FTSE Bursa Malaysia

    1,569.87
    +2.73 (+0.17%)
     
  • Jakarta Composite Index

    6,359.21
    +20.69 (+0.33%)
     
  • PSE Index

    6,919.54
    +46.57 (+0.68%)
     

ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm

·3-min read

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased AstraZeneca PLC (NASDAQ: AZN) American Depository Shares ("ADSs") between May 21, 2020 and November 20, 2020 (the "Class Period"). Investors have until March 29, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

AstraZeneca is one of the largest biopharmaceutical companies in the world and was one of the early front-runners in the race to develop a COVID-19 vaccine. In April 2020, the Company partnered with Oxford University to develop a potential recombinant adenovirus vaccine for the virus, later dubbed AZD1222.

On November 23, 2020, AstraZeneca issued a release announcing the results of an interim analysis of its ongoing trial for AZD1222. The announcement immediately began to raise questions among analysts and industry experts. AstraZeneca disclosed that the interim analysis involved two smaller scale trials in disparate locales (the United Kingdom and Brazil) that, for unexplained reasons, employed two different dosing regimens. One clinical trial provided patients a half dose of AZD1222 followed by a full dose, while the other trial provided two full doses. Counterintuitively, AstraZeneca claimed that the half dosing regimen was substantially more effective at preventing COVID-19 at 90% efficacy than the full dosing regimen, which had achieved just 62% efficacy.

In the days that followed, additional revelations were made regarding problems with AstraZeneca’s AZD1222 clinical trials. For example, the differing dosing regimens were revealed to be due to a manufacturing error rather than trial design. Also, the half-strength dose had not been tested in people over the age of 55 – despite the fact that this population was the most vulnerable to COVID-19. Moreover, certain trial participants received their second dose later than originally planned. U.S. regulators stated that if AstraZeneca could not clearly explain the discrepancies in its trial results, the results would most likely not be sufficient for approval for commercial sale in the United States.

As negative news reports continued to reveal previously undisclosed problems and flaws in AstraZeneca’s clinical trials for AZD1222, the price of AstraZeneca ADSs fell to $52.60 by market close on November 25, 2020, a 5% decline over three trading days in response to adverse news.

The complaint, filed on July 26, 2021, alleges that defendants misrepresented facts regarding the Company’s ongoing AZD1222 clinical trials and concealed problems that had arisen in the trials, including a dosing error which had been discovered early on by the Company but not disclosed to investors.

If you purchased AstraZeneca ADSs during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127006016/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com